Pharmac Consulting On Widening Access To Venetoclax, Azacitidine And Upadacitinib

Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently funded for other types of blood cancer.